An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group.

Aims: Previous risk models predicting in-hospital major adverse cardiac or cerebrovascular events (MACCE) after percutaneous coronary interventions (PCI) may underestimate actual short-term post-procedure complications due to the trend toward early discharge of patients.

Methods And Results: Using a subset (N=10,679) from the STENT Group registry, a logistic regression model was developed to predict 30-day MACCE which includes death, myocardial infarction, target vessel revascularisation and stroke. An integer-based risk score was created from the model and validated in another subset (N=3,099).

Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.

Objectives: This study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention.

Background: The safety and efficacy of DES in patients undergoing SVG intervention is controversial.

Methods: The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is a multicenter U.

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

Objectives: This study evaluates outcomes and complications in patients treated with drug-eluting stents (DES) for "off-label" indications.

Background: Drug-eluting stents have been effective in randomized trials, but their safety and efficacy for off-label indications has not been well studied.

Methods: The STENT (Strategic Transcatheter Evaluation of New Therapies) Registry is the largest multicenter U.

Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group.

Objectives: This study compares outcomes with drug-eluting stents (DES) versus bare metal stents (BMS) in patients with ST-elevation myocardial infarction (STEMI).

Background: DESs have been effective in elective percutaneous coronary intervention (PCI), but their safety and efficacy in patients with STEMI have not been well studied.

Methods: The STENT Registry is a multicenter United States registry evaluating outcomes of DES.

Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry--STENT Group.

Objectives: The purpose of this study was to compare the 9-month clinical outcomes of patients treated with paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES) for coronary artery stenosis.

Background: The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is the first multicenter registry in the U.S.